Literature DB >> 12515087

Diabetic macular edema: review and update.

Christopher Pelzek1, Jennifer I Lim.   

Abstract

Impairment in the visual acuity and quality of life of diabetic patients with macular edema can undeniably be decreased with systemic and ocular therapeutic intervention, as shown by numerous controlled studies. Such interventions, with early screening and periodic examination, are even more crucial given the increasing survival of patients with diabetic retinopathy. In the 1950s, adjusted 5-year survival rates for patients with PDR were less than 30%, whereas by the end of the century age- and sex-adjusted 5-year survival rates approached 90% for patients with early-onset diabetes and 60% for patients with late-onset diabetes [83]. Furthermore, advances in our understanding of diabetic retinopathy have led to biochemical adjuncts that offer the potential for further reduction of visual loss caused by diabetic macular edema. Despite such advances, the implementation of effective treatments has been hampered by concerns over hypoglycemia after intensive insulin regimens, poor physician compliance regarding guidelines for dilated ophthalmic examinations, and economic barriers to access [84]. Therefore, it is imperative for the ophthalmologist not only to discuss the progression and treatment of diabetic macular edema and the importance of routine examination with patients but also to work with other health care professionals to ensure the evaluation and treatment of associated cardiovascular and neurologic disease. Educational programs, such as those created by the National Eye Health and Education Program [85], may also assist the ophthalmologist in providing patients with the optimal care available in the 21st century.

Entities:  

Mesh:

Year:  2002        PMID: 12515087     DOI: 10.1016/s0896-1549(02)00043-3

Source DB:  PubMed          Journal:  Ophthalmol Clin North Am        ISSN: 0896-1549


  15 in total

1.  Pattern electroretinogram for monitoring the efficacy of intravitreal triamcinolone injection in diabetic macular edema.

Authors:  Abdullah Ozkiris; Cem Evereklioglu; Ayse Oner; Kuddusi Erkiliç
Journal:  Doc Ophthalmol       Date:  2004-09       Impact factor: 2.379

2.  Overexpression of pigment epithelium-derived factor inhibits retinal inflammation and neovascularization.

Authors:  Kyoungmin Park; Ji Jin; Yang Hu; Kevin Zhou; Jian-xing Ma
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

3.  Prediction of postoperative visual outcome after pars plana vitrectomy based on preoperative multifocal electroretinography in eyes with diabetic macular edema.

Authors:  Yong Min Kim; Soo Young Lee; Hyoung Jun Koh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-05-06       Impact factor: 3.117

4.  Macular hole in juvenile X-linked retinoschisis.

Authors:  Nayef Al-Swaina; Sawsan R Nowilaty
Journal:  Saudi J Ophthalmol       Date:  2013-05-30

Review 5.  Statement of the German Ophthalmological Society, the German Retina Society, and the Professional Association of Ophthalmologists in Germany on treatment of diabetic macular edema : Dated August 2019.

Authors: 
Journal:  Ophthalmologe       Date:  2021-01       Impact factor: 1.059

6.  Pattern electroretinogram changes after intravitreal bevacizumab injection for diabetic macular edema.

Authors:  Abdullah Ozkiriş
Journal:  Doc Ophthalmol       Date:  2010-02-07       Impact factor: 2.379

7.  Review of therapeutic advances in diabetic retinopathy.

Authors:  Chirag P Shah; Carolyn Chen
Journal:  Ther Adv Endocrinol Metab       Date:  2011-02       Impact factor: 3.565

Review 8.  Sustained-release ophthalmic drug delivery systems for treatment of macular disorders: present and future applications.

Authors:  Blake A Booth; Lori Vidal Denham; Saadallah Bouhanik; Jean T Jacob; James M Hill
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

9.  Systemic administration of HMG-CoA reductase inhibitor protects the blood-retinal barrier and ameliorates retinal inflammation in type 2 diabetes.

Authors:  Jingming Li; Joshua J Wang; Danyang Chen; Robert Mott; Qiang Yu; Jian-xing Ma; Sarah X Zhang
Journal:  Exp Eye Res       Date:  2009-02-28       Impact factor: 3.467

10.  Short-term results of intravitreal dexamethasone implant (OZURDEX(®)) in treatment of recalcitrant diabetic macular edema: A case series.

Authors:  Pukhraj Rishi; Ekta Rishi; Lakshmi Kuniyal; Gaurav Mathur
Journal:  Oman J Ophthalmol       Date:  2012-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.